RSF1 and Not Cyclin D1 Gene Amplification May Predict Lack of Benefit from Adjuvant Tamoxifen in High-Risk Pre-Menopausal Women in the MA.12 Randomized Clinical Trial

Most women with estrogen receptor expressing breast cancers receiving anti-estrogens such as tamoxifen may not need or benefit from them. Besides the estrogen receptor, there are no predictive biomarkers to help select breast cancer patients for tamoxifen treatment. CCND1 (cyclin D1) gene amplificat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Keilty, Dana, Buchanan, Marguerite, Ntapolias, Katerina, Aleynikova, Olga, Tu, Dongsheng, Li, Xiao, Shepherd, Lois, Bramwell, Vivien, Basik, Mark
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3868649/
https://ncbi.nlm.nih.gov/pubmed/24367492
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0081740
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares